尽管65岁以上的患者占乳腺癌患者的大多数，我们对该人群肿瘤内科治疗的安全性和有效性的数据有限.他们的适应症主要基于专家协议。这篇文献综述讨论了乳腺癌主要药物治疗的安全性和有效性的已知数据：化疗，细胞因子依赖性激酶抑制剂4/6，靶向人表皮生长因子受体2的药物，新型抗体偶联物，和免疫疗法。
Although patients over 65 years of age represent the majority of breast cancer patients, we have limited data on the safety and efficacy of medical oncology treatments in this population. Their indications are based primarily on expert agreement. This literature review discusses the known data on the safety and efficacy of the main medical treatments for breast cancer: chemotherapy, cytokine-dependent kinase inhibitors 4/6, agents targeting human epidermal growth factor receptor-2, novel antibody conjugates, and immunotherapy.
